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ABSTRACT
OBJECTIVES The authors sought to provide the pre-speciﬁed primary endpoint of the ROADMAP (Risk Assessment and
Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure
Patients) trial at 2 years.
BACKGROUND The ROADMAP trial was a prospective nonrandomized observational study of 200 patients (97 with a
left ventricular assist device [LVAD], 103 on optimal medical management [OMM]) that showed that survival with
improved functional status at 1 year was better with LVADs compared with OMM in a patient population of ambulatory
New York Heart Association functional class IIIb/IV patients.
METHODS The primary composite endpoint was survival on original therapy with improvement in 6-min walk
distance $75 m.
RESULTS Patients receiving LVAD versus OMM had lower baseline health-related quality of life, reduced Seattle Heart
Failure Model 1-year survival (78% vs. 84%; p ¼ 0.012), and were predominantly INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) proﬁle 4 (65% vs. 34%; p < 0.001) versus proﬁles 5 to 7. More LVAD patients
met the primary endpoint at 2 years: 30% LVAD versus 12% OMM (odds ratio: 3.2 [95% conﬁdence interval: 1.3 to 7.7];
p ¼ 0.012). Survival as treated on original therapy at 2 years was greater for LVAD versus OMM (70  5% vs. 41  5%;
p < 0.001), but there was no difference in intent-to-treat survival (70  5% vs. 63  5%; p ¼ 0.307). In the OMM
arm, 23 of 103 (22%) received delayed LVADs (18 within 12 months; 5 from 12 to 24 months). LVAD adverse events
declined after year 1 for bleeding (primarily gastrointestinal) and arrhythmias.
CONCLUSIONS Survival on original therapy with improvement in 6-min walk distance was superior with LVAD compared
with OMM at 2 years. Reduction in key adverse events beyond 1 year was observed in the LVAD group. The ROADMAP trial
provides risk-beneﬁt information to guide patient- and physician-shared decision making for elective LVAD therapy as a
treatment for heart failure. (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical
Management in Ambulatory Heart Failure Patients [ROADMAP]; NCT01452802) (J Am Coll Cardiol HF 2017;5:518–27)
© 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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T he ROADMAP (Risk Assessment and Compar-ative Effectiveness of Left Ventricular AssistDevice and Medical Management in Ambula-
tory Heart Failure Patients) study’s 1-year results
showed that survival with improved functional status
at 1 year was better with left ventricular assist devices
(LVADs) compared with optimal medical manage-
ment (OMM) in a patient population of ambulatory
New York Heart Association (NYHA) functional class
IIIB/IV patients who were not dependent on intrave-
nous inotropic support (1). Survival was similar in
both groups in the intention-to-treat analysis. How-
ever, as-treated event-free actuarial survival over a
1-year period was signiﬁcantly better with LVAD
than OMM (80  4% vs. 63  5%). Differences in the
primary endpoint between LVAD and OMM were pri-
marily due to the use of delayed LVADs in the OMM
group. Factors beyond survival seem paramount to
decision making surrounding LVAD implantation in
this ambulatory patient population. At 1-year
follow-up, patients in the OMM group avoided LVAD
surgery and LVAD-associated adverse events (AEs);
however, patients observed on OMM did not achieve
the primary beneﬁts of functional improvements
and patient-reported health-related quality of life
(HRQoL) with LVAD support. To better understand
the long-term beneﬁts and risks of LVAD compared
with OMM, we now provide the pre-speciﬁed primary
endpoint and other important study results after
2 years of follow-up.
METHODS
STUDY DESIGN. The ROADMAP study was a prospec-
tive, multicenter (N¼ 41), nonrandomized, controlled,
observational study to evaluate the effectiveness of
LVAD versus OMM (2). Enrollment began in
October 2011 with patients being followed for
up to 2 years. The primary composite endpoint
was survival with improvement in 6-min walk
distance (6MWD) $75 m at 1 year, which has
been previously published (1). This report
focuses on the primary endpoint at 2 years
and secondary study endpoints, which
include actuarial survival, HRQoL, depres-
sion, functional status, and AEs, after 2 years
of follow-up.
STUDY SUBJECTS. In addition to meeting
U.S. Food and Drug Administration–approved
indications for HeartMate II LVAD (Thoratec
[now Abbott], Pleasanton, California) desti-
nation therapy, entrance criteria included
NYHA functional class IIIB/IV, at least 1
hospitalization for heart failure (HF) (or 2 un-
scheduled emergency department/infusion
clinic visits) in the last 1 year, and 6MWD<300
m. Subjects were excluded if there was ino-
trope use within 30 days before enrollment. Of
the 200 patients enrolled, 97 selected LVAD therapy
and 103 remained onmedicalmanagement in the OMM
arm. Patients in the OMM cohort could receive a
delayed LVAD at any point during the study period.
BASELINE AND FOLLOW-UP ASSESSMENTS. Baseline
assessments included demographic characteristics,
medical history, NYHA functional class, INTERMACS
(Interagency Registry for Mechanically Assisted Cir-
culatory Support) proﬁle, 6MWD, serum chemistry,
hematologic data, and medications. Patients also
completed a HRQoL survey, the EuroQol 5 dimensions,
5-level questionnaire (EQ-5D-5L) including the visual
AB BR E V I A T I O N S
AND ACRONYM S
6MWD = 6-min walk distance
AE = adverse event
eppy = events per patient-year
EQ-5D = EuroQol 5 dimensions
questionnaire
GI = gastrointestinal
HF = heart failure
HRQoL = health-related
quality of life
HTx = heart transplantation
LVAD = left ventricular assist
device
NYHA = New York Heart
Association
OMM = optimal medical
management
PHQ-9 = Patient Health
Questionnaire
QoL = quality of life
VAS = visual analog scale
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analog scale (VAS), and a depression screening ques-
tionnaire, the Patient Health Questionnaire (PHQ-9).
A summary of baseline patient characteristics has been
previously published (1). Clinical follow-up took place
every 6 months for up to 2 years and included assess-
ment of HRQol, depression, functional status, and
laboratory parameters. Prevalence, incidence, causes
of rehospitalizations, and causes of death were docu-
mented by study sites, but not adjudicated. AEs were
captured using standardized INTERMACS deﬁnitions
as reported by investigators.
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD or SE, or median and quartiles,
and categorical data are reported as percentages.
Differences between groups were analyzed by the
Fisher exact test. Differences between groups of in-
dependent, normally distributed, continuous vari-
ableswere evaluated using the 2-sample Student t test.
Variables that were not normally distributed were
compared between treatments using the Wilcoxon
rank sum test. A 2-sided p value <0.05 is signiﬁcant.
The primary endpoint evaluated at 2 years was a
composite of survival and improvement in 6MWD
of $75 m. Urgent heart transplantation (HTx) and
explant after LVAD complications in LVAD patients
were considered treatment failures. Receipt of
delayed LVADs and urgent HTx in OMM patients were
also considered treatment failures. Patients who
withdrew from the study were excluded from the
2-year primary endpoint analysis.
Actuarial survival as treated on original therapy
was performed with the Kaplan-Meier method for
LVAD patients free of urgent HTx or explant, and
for OMM patients free of LVAD implantation or urgent
HTx. Intent-to-treat survival was also determined
through 2 years post-enrollment. Differences be-
tween groups were determined with the log-rank test.
The prevalence of patients with AEs within
2 years and the incidence rate of events per patient-
year (eppy) were determined for both groups.
A composite event rate was calculated as the sum
of eppy for bleeding, driveline infection, pump
thrombus, stroke, arrhythmias, and worsening HF.
Risk ratio evaluation and comparison of AE rates
were performed using Cochran-Mantel-Haenszel
statistics.
Paired changes in 6MWD, PHQ-9, and EQ-5D VAS
from baseline to 2 years were compared between pa-
tients surviving to 2 years on original therapy using
FIGURE 1 Roadmap Study Patients at 2 Years
HTx ¼ heart transplantation; LVAD ¼ left ventricular assist device; OMM ¼ optimal medical management; VAD ¼ ventricular assist device.
TABLE 1 Primary Endpoint Evaluated at 2 Years
OMM
(n ¼ 77)
LVAD
(n ¼ 67)
Alive at 2 yrs on original therapy with
increase in 6MWD by 75 m
9 (12) 20 (30)
(OR: 3.2 [95% CI: 1.3
to 7.7]; p ¼ 0.012)
First event that prevented success: 68 (88) 47 (70)
Death in 1st yr 18 (23) 17 (25)
Death in 2nd yr 13 (17) 8 (12)
Urgent HTx in 1st yr 0 (0) 2 (3)
Urgent HTx in 2nd yr 1 (1) 1 (2)
Delayed LVAD in 1st yr* 18 (23) NA
Delayed LVAD in 2nd yr 5 (7) NA
D 6MWT <75 m at 2 yrs 13 (17) 19 (28)
Values are n (%). Excluded OMM patients: 13 withdrawn, 13 missing 6MWD. Excluded LVAD
patients: 4 withdrawn, 5 elective HTx/explant, 21 missing 6MWD. *1 total artiﬁcial heart included.
6MWD ¼ 6-min walk distance; CI ¼ conﬁdence interval; HTx ¼ heart transplantation;
LVAD ¼ left ventricular assist device; NA ¼ not applicable; OMM ¼ optimal medical management;
OR ¼ odds ratio.
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mixed-effects modeling on ranks with Tukey adjust-
ment for pairwise comparisons. Post hoc composite
endpoints of favorable outcomes at 2 years were
determined, deﬁned as patients alive on original
therapy at 2 years with improvement in NYHA func-
tional class, increase in VAS of more than 20 points in
subjects with impaired HRQoL at baseline as deﬁned
by baseline VAS <68 (top quartile of values), and
depression score improvement of at least 5 points in
patients at baseline with at least mild depression
(PHQ-9 $5). A biostatistician independent of the
sponsor and the investigators provided an indepen-
dent validation of study results.
RESULTS
STUDY COURSE. A chart of all patients and main
outcomes over the 2-year study period is shown in
Figure 1. Of the 103 OMM patients, 18 died, 18
received delayed LVADs, and 9 withdrew during the
ﬁrst year. During the second year, an additional 13
OMM patients died, 5 received delayed LVADs, 1
received a HTx, and 4 withdrew from the study. Of
the 97 LVAD patients, 17 died, 3 received HTx, and 3
withdrew during the ﬁrst year of the study. Of the 74
patients remaining on LVAD support at 1 year, an
additional 8 died, 4 received HTx, 1 was explanted,
and 1 withdrew from the study during the second
year. At the end of 2 years, 35 (34%) OMM patients
and 60 (62%) LVAD patients were alive on their
original therapy.
PRIMARY ENDPOINT. At 2 years, more LVAD patients
(30%) met the primary endpoint of alive on original
therapy with improvement in 6MWD of at least 75 m
than OMM patients (12%) (odds ratio: 3.2 [95% conﬁ-
dence interval: 1.3 to 7.7]; p ¼ 0.012). The main reason
for fewer OMM patients meeting the primary endpoint
compared with the LVAD group was the use of delayed
LVADs. In the second year, a larger percentage of
deaths and additional delayed LVAD implants in OMM
patients contributed to fewer OMM patients meeting
the primary endpoint at 2 years (Table 1). A sensitivity
analysis for the effect of missing data on the primary
endpoint is shown in Online Table 1. Signiﬁcantly
more LVAD patients met the primary endpoint
compared with OMM patients even when those with-
drawn from the study or with missing 6-min walk test
were counted as either treatment successes or failures.
ACTUARIAL SURVIVAL. Twenty-four-month survival
as treated on original therapy (event-free survival) was
greater for LVAD versus OMM (70  5% vs. 41  5%;
p < 0.001) (Figure 2). There was no difference in
intent-to-treat survival for LVAD versus OMM
(70 5% vs. 63 5%; p¼ 0.307) (Figure 3). A competing
outcomes analysis for all LVAD and OMM patients is
also shown in Online Figure 1.
FUNCTIONAL STATUS AND QUALITY OF LIFE. At 2
years, in patients still on original therapy, LVAD
FIGURE 3 Intention-to-Treat Survival
Abbreviations as in Figures 1 and 2.
FIGURE 2 Survival as Treated
HR ¼ hazard ratio; other abbreviations as in Figure 1.
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patients experience greater improvements in func-
tional status and quality of life (QoL) compared with
OMM patients. At study enrollment, no patients were
in NYHA functional class I or II. By 2 years, 69% of
LVAD patients had improved to class I or II, which
was signiﬁcantly >37% of the remaining OMM pa-
tients (p < 0.01) (Figure 4). LVAD patients exhibited a
signiﬁcant increase in 6MWD from baseline by an
average of 74 m (p < 0.05) after 2 years of support
compared with no signiﬁcant change in OMM patients
(Table 2).
Baseline health-related QoL measures are shown in
Table 2. The EQ-5D VAS increased signiﬁcantly more
for LVAD versus OMM at 2 years with an average
improvement of 27 points for LVAD patients
compared with 8 points for OMM patients (p < 0.001)
(Table 2). At 2 years, the PHQ-9 depression score for
LVAD patients improved signiﬁcantly from enroll-
ment by an average of 4.6 points, with no signiﬁcant
change in OMM patients (Table 2).
The primary and secondary composite endpoints
showing the percentage of patients alive at 2 years on
original therapy with improvements in NYHA func-
tional class, EQ-5D VAS, and depression all showed
signiﬁcant improvements in LVAD versus OMM
patients (Figure 5).
DELAYED VADs. The 22 patients with delayed VADs
(not including the 1 with a total artiﬁcial heart)
received implants after a median time from enroll-
ment of 4.9 (min to max: 1.2 to 19.7) months (Table 3).
The median INTERMACS proﬁle at enrollment was 5
(min to max: 4 to 6) and dropped to 4 (min to max:
2 to 6) at the time of implantation. Fifty-ﬁve percent
of OMM patients receiving delayed VADs were ino-
trope dependent when they received implants, but
45% remained INTERMACS 4 to 6. Median Seattle
Heart Failure Model–predicted survival dropped from
89% (quartile 1 to 3: 81% to 92%) at enrollment to 71%
(quartile 1 to 3: 40% to 86%) before delayed implant,
TABLE 2 Paired Changes in 6MWD, EQ-5D VAS, and PHQ-9 Scores in 2-Yr Survivors on
Original Therapy
Arm
N
(Missing N) Baseline 2 Yrs Change
p Value
Within Arm
6MWD (m) OMM 22 (13) 213  81 277  106 64  103 0.312
LVAD 39 (21) 180  88 254  134 74  141 0.030
p Value between arms 0.622 0.869 0.768
EQ-5D VAS OMM 28 (7) 66  18 74  18 8  20 0.282
LVAD 53 (7) 44  19 71  21 27  24 <0.001
p Value between arms <0.001 0.787 <0.001
PHQ-9 score OMM 27 (8) 6.8  6.4 5.0  5.7 1.8  6.3 0.480
LVAD 54 (6) 10.0  5.6 5.4  5.6 4.6  6.9 <0.001
p Value between arms 0.055 0.958 0.084
A lower PHQ-9 score indicates lower depression.
EQ-5D VAS ¼ EuroQol 5 dimensions questionnaire–visual analog scale; PHQ-9 ¼ Patient Health Questionnaire;
other abbreviations as in Table 1.
FIGURE 4 Changes in NYHA Classiﬁcation in Patients Who Are Alive on Original Therapy at 2 Years
NYHA ¼ New York Heart Association; other abbreviations as in Figure 1.
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and median 6MWD decreased from 219 (quartile 1 to
3: 192 to 272) m to 90 (quartile 1 to 3: 0 to 221) m before
implantation. There were no deaths within 30 days
after delayed LVAD, and survival at 1 year was 90 
6%, which was not different from the original LVAD
cohort (p ¼ 0.33 log-rank). Additional comparisons of
baseline characteristics of LVAD patients implanted
at enrollment and before implantation in the delayed
group are shown in Online Table 2. Survival curves of
both groups are shown in Online Figure 2.
ADVERSE EVENTS. Table 4 lists the prevalence and
cumulative AE rates for the entire 2-year follow-up
period. Over the 2-year study, the composite event
rate was signiﬁcantly higher for LVAD versus OMM
(1.74. vs 0.98 eppy; p < 0.001). Gastrointestinal (GI)
bleeding is the most common AE for LVAD patients,
and 5 patients contributed more than one-half of all GI
bleeding events in the LVAD group. Worsening HF is
the most frequent event for OMM patients. Table 5
shows the AE occurrence in the ﬁrst and the second
year of follow-up. The AE proﬁle for OMM did not
change signiﬁcantly over time. In LVAD patients, there
was no change in pump thrombus or driveline infec-
tion rates from the ﬁrst to second year. However, LVAD
event rates for GI bleeding and ventricular
arrhythmias decreased signiﬁcantly from the ﬁrst to
second year. As a result, the composite event rate was
no longer signiﬁcantly different between LVAD and
OMM in the second year of follow-up. Right HF also
showed a trend for reduction in the second year.
LVAD patients had more hospitalizations than OMM
patients throughout the study. Freedom from re-
hospitalization at 2 years (Online Figure 3) was 16% for
OMM patients and 8% for LVAD patients (p ¼ 0.005).
The main reason for readmission of OMM patients was
worsening HF. Hospitalizations for LVAD patients
were largely due to AEs (predominantly bleeding). In
the second year, there was a decrease in the number of
LVAD patient readmissions related to AEs (Table 6).
Of the 25 LVAD patients who expired, the leading
cause of death was infection (n¼ 6), followed by stroke
(n ¼ 3), device thrombosis (n ¼ 3), multiorgan failure
(n ¼ 3), HF (n ¼ 3), and 1 each for bleeding, driveline
disconnect, ventricular ﬁbrillation, pleural effusion,
respiratory failure, car accident, and unknown. The
most common cause of death among the 31 OMM pa-
tientswho expiredwasworseningHF (n¼21), followed
by cancer (n ¼ 2), 1 each for sudden cardiac death,
chronic obstructive pulmonary disease, sepsis, multi-
organ failure, and bleeding, and 3 were unknown.
RISK–BENEFIT ANALYSIS. Figure 6 summarizes the
beneﬁts and risks of LVAD therapy versus OMM for
patients in the ROADMAP study. In the second year of
the ROADMAP study, LVAD patients continue to be
more likely to reach the primary composite endpoint
and their survival as treated on original therapy is
signiﬁcantly better. LVAD patients also continue to be
more likely to show improvements in NYHA func-
tional class, HRQoL, and depression at 2 years
compared with OMM patients. The composite AE rate
during the second year between LVAD and OMM
patients is not signiﬁcantly different.
DISCUSSION
The principal ﬁndings after 2 years of follow-up in the
ROADMAP study include: 1) higher survival with
FIGURE 5 Primary and Secondary Composite Endpoints
Primary (A) and secondary (B, C, D) composite endpoints. 6MWD ¼ 6-min walk distance;
OR ¼ odds ratio; PHQ ¼ Patient Health Questionnaire; VAS ¼ visual analog scale; other
abbreviations as in Figures 1 and 4.
TABLE 3 Paired Changes in OMM Patients Receiving Delayed VAD
All Delayed LVAD Patients (N ¼ 22)
Time to Implantation ¼ 4.9 [2.7–12.4] Months
Enrollment Delayed Implantation Paired p Value
Inotrope dependent 22 0 (0) 12 (55) <0.001
INTERMACS proﬁle 18 5 [4–6] 4 [2–4] <0.001
NYHA functional class IV 20 5 (25) 14 (70) 0.004
SHFM 1-yr survival (%)* 22 89 [81–92] 71 [40–86] 0.001
Albumin (g/dl) 20 3.9 [3.6–4.2] 3.5 [3.4–3.7] 0.009
6MWD (m) 15 219 [192–272] 90 [0–221] <0.001
VAS 13 45 [33–50] 40 [28–50] 0.473
PHQ-9 15 7 [2–10] 9 [4–12] 0.423
Values are n, n (%), or median [quartile 1 to 3]. *Mean predicted survival was 85  11% at
enrollment and 61  31% at delayed implant.
INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory Support;
SHFM ¼ Seattle Heart Failure Model; VAD ¼ ventricular assist device; other abbreviations as in
Tables 1 and 2.
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improved functional status, improved QoL, and
reduced depression in the LVAD group; 2) no
increased mortality with delaying LVAD implant
while being monitored closely; 3) more hospitaliza-
tions in the LVAD than the OMM group throughout
the study; and 4) greater rate of major AEs in
LVAD than OMM subjects in year 1 but with a reduc-
tion in LVAD AEs in year 2. The second-year
ROADMAP study results demonstrate the beneﬁt of
the HeartMate II LVAD in select functionally limited
non–inotrope-dependent HF patients.
Advanced HF is a lethal condition with few options
to extend survival and QoL; due to donor shortage,
heart transplantation is limited to a fraction of the
patients in need. The advent of continuous-ﬂow
LVAD therapy heralded the hope to save many lives,
and initial encouraging reports sparked a prolifera-
tion of LVAD implantations (3–6). Enthusiasm grew
with new devices, and subsequently, a National
Heart, Lung, and Blood Institute workshop was
convened to design a clinical trial to determine
whether LVAD use could be safely expanded to “less
ill” patients (7). The REVIVE-IT (Registry Evaluation
of Vital Information for VADS in Ambulatory Life;
NCT01369407) trial intended to compare the effec-
tiveness of LVAD and medical therapy in non–
inotrope-dependent patients through a design
randomizing patients to the 2 respective treatment
approaches. The REVIVE-IT trial faced numerous
challenges and was never completed, and has evolved
into a registry. The ROADMAP study was conceived at
the same time and designed as a nonrandomized trial
in which patients and their physicians could deter-
mine the choice of LVAD versus OMM therapy, and
outcomes of these choices would be carefully
assessed. Our goals included determining functional
capacity, and the primary endpoint included a clini-
cally relevant incremental walk distance of 75 m on
original therapy. Detailed efforts were made to collect
data to understand why both physicians and patients
chose a therapy and to capture patient-reported
outcomes.
The observation that LVADpatientsmore oftenmet the
primary endpoint was anticipated and not surprising
based on the 1-year results (1). This ﬁnding was also sus-
tained at 2 years with more LVAD patients on original
therapy alive and able to walk with an improvement of
more than 75 m. For this non–inotrope-dependent popu-
lation, LVAD mortality in the initial 30 days was a
remarkably low 1%; however, the observed AE rates
remain similar to what has been reported with contem-
porary devices (3,4,8–12). What is provocative is that
despite the LVAD cohort having more AEs, frequent hos-
pitalizations, and worse pre-LVAD self-reported QoL,
LVAD therapy resulted in greater improvement in
depression and inQoL at both 1 and 2 years comparedwith
OMM, although potential bias in these types of assess-
ments must be recognized. The AEs at 2 years in patients
choosing LVAD included 11% stroke, 12% LVAD
TABLE 4 Cumulative AEs Within 2 Yrs of Enrollment
OMM (n ¼ 103)
Patients (%) (eppy)
LVAD (n ¼ 94)
Patients (%) (eppy)
DT Trial as Reference
(eppy)*
Bleeding 3 (3) (0.02) 51 (54) (1.09)† 1.13
GI bleeding 2 (2) (0.02) 31 (33) (0.68‡)† NA
Driveline infection NA 16 (17) (0.15)† 0.22
Pump thrombus NA 11 (12) (0.08)‡‡ 0.07§
Within 90 days 1 (1.1)
Pump replacement†† 7 (7.4)
Stroke 4 (3.9) (0.03) 11 (11.7) (0.09) 0.08
Ischemic 3 (2.9) (0.02) 8 (8.5) (0.06) 0.05
Hemorrhagic 1 (1.0) (0.01) 4 (4.3) (0.03) 0.03
Arrhythmias VT/VF 13 (13) (0.12) 21 (22) (0.21) 0.46
Worsening heart failurek 51 (50) (0.80) 13 (14) (0.13)† NA
Right heart failure¶ 3 (3) (0.02) 10 (11) (0.07) 0.13
Rehospitalizations 78 (76) (1.51) 81 (86) (2.55)† 2.64#
“Composite” event rate** 55 (53) (0.98) 72 (77) (1.74)† 2.09
Relative risk [95% CI] OMM/LVAD: 0.56 [0.41–0.77]†
*Park et al. (4). †p < 0.001. ‡Five patients had w50% of GI bleeding events. §Thrombus þ hemolysis.
kWorsening HF: symptoms resulting in unexpected hospitalization, emergency room visit, or urgent clinic visit
requiring intravenous therapy for HF. ¶Right HF: symptoms and signs of persistent right ventricular dysfunction
requiring right VAD implantation or requiring inhaled nitric oxide or inotropic therapy. #Slaughter et al. (3). **Sum
of bleeding, driveline infection, thrombus, stroke, arrhythmias, and worsening HF. ††For thrombus, there were 2
additional pump replacements for infection and percutaneous lead failure. ‡‡p < 0.01
AE ¼ adverse event; CI ¼ conﬁdence interval; DT ¼ Destination Therapy; eppy ¼ events per patient-year;
GI ¼ gastrointestinal; HF ¼ heart failure; VT/VF ¼ ventricular tachycardia/ventricular ﬁbrillation; other
abbreviations as in Table 1.
TABLE 5 AEs During the First and Second Yr of Follow-Up
Yr 1 Yr 2
OMM
AE Rate (eppy)
79.7 Patient-Yrs
LVAD
AE Rate (eppy)
82.4 Patient-Yrs
OMM
AE Rate (eppy)
45.2 Patient-Yrs
LVAD
AE Rate (eppy)
68.7 Patient-Yrs
Bleeding 0.03 1.49* 0.02 0.60*†
GI bleeding 0.01 0.92* 0.02 0.39*†
Infection 0.09 0.97* 0.13 0.68*
Driveline infection NA 0.13§ NA 0.17§
Sepsis 0.01 0.23* 0 0.13‡
Pump thrombus NA 0.07‡ NA 0.09
Stroke 0.025 0.12‡ 0.04 0.04
Ischemic 0.013 0.07 0.04 0.04
Hemorrhagic 0.013 0.05 0 0
Arrhythmias VT/VF 0.10 0.33§ 0.16 0.07†
Worsening heart failure 0.90 0.16* 0.62 0.09*
Right heart failure 0.03 0.11‡ 0.02 0.01
Rehospitalizations 1.77 2.67‡ 1.04† 2.40*
“Composite” event ratek 1.05 2.31* 0.84 1.06¶
Relative risk [95% CI] OMM/LVAD: 0.46 [0.31–0.68]* OMM/LVAD: 0.79 [0.46–1.36]
*p < 0.001 (OMM vs. LVAD). †p < 0.05 (yr 2 vs. yr 1). ‡p < 0.05 (OMM vs. LVAD). §p < 0.01 (OMM vs. LVAD).
kSum of bleeding, driveline infection, thrombus, stroke, arrhythmias, and worsening HF. ¶p < 0.001 (yr 2 vs. yr 1).
Abbreviations as in Tables 1 and 4.
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thrombosis, 22% arrhythmias, 33% GI bleeding, and 86%
requiredhospitalization,whereasof thosechoosing tostay
on OMM, 50% experienced worsening HF, 13% arrhyth-
mias, 4% stroke, and 76% also required hospitalization.
AEs/complications remain a challenge for LVAD therapy
(13). However, we are encouraged that in the ROADMAP
study, there was a reduction in AEs in the second
year of follow-up; this observation was also noted in a
FIGURE 6 Risk-Beneﬁt Analysis
CI ¼ conﬁdence interval; R.R. ¼ risk ratio; other abbreviations as in Figures 1, 2, 4, and 5.
TABLE 6 Reasons for Rehospitalizations
Yr 1 Yr 2
OMM (n ¼ 141) LVAD (n ¼ 220) OMM (n ¼ 47) LVAD (n ¼ 165)
Adverse events 85 (60) 1.07 142 (65) 1.72 32 (68) 0.71 92 (56) 1.34
Elective procedure 10 (7) 0.13 15 (7) 0.18 1 (2) 0.02 15 (9) 0.22
Comorbidity management 10 (7) 0.13 10 (5) 0.12 4 (9) 0.09 12 (7) 0.17
Blood pressure/volume management 4 (3) 0.05 12 (5) 0.15 0 (0) 0 4 (2) 0.06
Pain 4 (3) 0.05 4 (2) 0.05 2 (4) 0.04 12 (7) 0.17
Trauma 1 (1) 0.01 4 (2) 0.05 2 (4) 0.04 9 (5) 0.13
LVAD alarms/driveline and controller problems 0 (0) 0 5 (2) 0.06 0 (0) 0 7 (4) 0.10
Dizziness/syncope 9 (6) 0.11 7 (3) 0.08 0 (0) 0 2 (1) 0.03
LVAD implantation or exchange/heart transplantation 10 (7) 0.13 2 (1) 0.02 3 (6) 0.07 6 (4) 0.09
Anticoagulation management 0 (0) 0 6 (3) 0.07 0 (0) 0 2 (1) 0.03
Rehabilitation/hospice 3 (2) 0.04 5 (2) 0.06 1 (2) 0.02 1 (1) 0.01
Other 5 (4) 0.06 8 (4) 0.10 2 (4) 0.04 3 (2) 0.04
Values are events (%) eppy.
Abbreviations as in Tables 1 and 4.
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single-center report with a reduction in AEs after 6
months (8).
The results show there was no increase in mortality
in the delayed LVAD group compared with the orig-
inal LVAD group post-implant. The delayed LVAD
patients were enrolled in the OMM arm with a median
INTERMACS proﬁle of 5. At the time of delayed LVAD
implantation (a median of 4.9 months after enroll-
ment), the median INTERMACS proﬁle had changed
incrementally to 4, which is the same as the original
LVAD cohort at implantation. Thus, one would expect
similar survival rates post-LVAD. Patients implanted
with LVADs later in the ROADMAP study are not
delayed compared with standard clinical practice,
where most patients today are inotrope dependent in
proﬁles 2 or 3. Hence, results cannot be generalized to
patients with greater clinical deterioration before
implantation.
The ROADMAP study has demonstrated that
patients may make choices contrary to what might be
intuitive to the physician. Patients who are living
with HF may be willing to accept a burden of AEs to
improve their functional capacity and QoL. Earlier
referral enables better education and shared decision
making with the patient, which is important for
weighing beneﬁts and risks of LVAD therapy. Patients
may be willing to accept a “trade off”: improvement
in QoL and functional capacity versus potential AEs.
Bruce et al. (14) described the importance of a patient-
centered perspective and discussions that include 3
domains for patient education and decision making
regarding LVADs: survival, functional capacity/QoL,
and AEs. The importance of developing decision aids
for patients with advanced HF considering the
extremely complex process and lifestyle of LVAD
therapy has been highlighted recently (15).
STUDY LIMITATIONS. The study was nonrandomized;
hence, a potential exists for bias regarding patient
selection and patient-reported outcomes including
HRQoL and depression, which were nonblinded.
There was a high withdrawal rate from the study,
with more withdrawing in the OMM arm than in the
LVAD arm, thus introducing a potential bias. How-
ever, if the primary endpoint is reanalyzed counting
all withdrawn patients as treatment failures, the
study ﬁndings are maintained, with more LVAD than
OMM patients still meeting the endpoint (28% vs.
10%; odds ratio: 3.5 [95% conﬁdence interval: 1.5 to
8.4]; p ¼ 0.004) (Online Table 1). Data were also
missing for some endpoints, including the 6-min walk
test, as noted in Table 2, which could have an effect
on the results. The event free survival analysis did
not include pump replacement as an event. However,
if pump replacement is included, event-free survival
for LVAD patients remains signiﬁcantly higher than
for OMM patients (Online Figure 4). AEs were re-
ported by treating physicians and not adjudicated by
a clinical events committee. Patient management was
per center practices, thus variations in medical man-
agement, anticoagulation, bleeding, and other events
may not have been attributed solely to patient or
device characteristics. Nonetheless, the ROADMAP
study provides important information for clinicians
prescribing LVAD therapy. Some patients and clini-
cians were not at equipoise and either believed LVAD
therapy was superior or that OMM therapy was su-
perior, and they made decisions based on this belief.
Many HF specialists feel that current LVAD technol-
ogy is not ready to be utilized in randomized trials of
less-sick patients, but the severity of illness of the
target patient population is a critical factor. On the
basis of our observed 24-month intent-to-treat sur-
vival in LVAD (70%) and OMM (63%) patients, a trial
would be difﬁcult to enroll, and would need to
randomize approximately 700 patients in each arm to
have 80% power to demonstrate a signiﬁcant differ-
ence in 2-year survival. However, if restricted
to INTERMACS proﬁle 4 patients, where our observed
intent-to-treat survival was 66% in LVAD and 49% in
OMM patients, a trial would only need to randomize
approximately 130 patients in each arm to show such
a difference.
CONCLUSIONS
The ROADMAP study has demonstrated the role of
LVAD therapy in non–inotrope-dependent patients
with advanced HF to improve functional capacity and
QoL, albeit with concomitant AEs. Delaying the de-
cision for LVAD therapy when monitored closely by a
HF specialist with access to LVAD therapy and
transplantation does not impair survival, though it
does delay QoL and functional improvements. The
need for a randomized clinical trial in expanded
patient populations that are not inotrope dependent
remains. Hopefully, such trials can be realized with
the emerging generation of LVADs, which new tech-
nology shows promise for reduced AEs (16–18).
ADDRESS FOR CORRESPONDENCE: Dr. Randall C.
Starling, Kaufman Center for Heart Failure, Heart and
Vascular Institute, Cleveland Clinic, 9500 Euclid
Avenue, Desk J3-4, Cleveland, Ohio 44195. E-mail:
starlir@ccf.org.
Starling et al. J A C C : H E A R T F A I L U R E V O L . 5 , N O . 7 , 2 0 1 7
The ROADMAP Study 2-Year Results: LVAD vs. Medical Therapy J U L Y 2 0 1 7 : 5 1 8 – 2 7
526
Downloaded for Anonymous User (n/a) at Virginia Commonwealth University - JMU Cooperative from ClinicalKey.com by Elsevier on July 20, 2017.
For personal use only. No other uses without permission. Copyright ©2017. Elsevier Inc. All rights reserved.
RE F E RENCE S
1. Estep JD, Starling RC, Horstmanshof DA, et al.
Risk assessment and comparative effectiveness of
left ventricular assist device and medical man-
agement in ambulatory heart failure patients:
results from the ROADMAP study. J Am Coll
Cardiol 2015;66:1747–61.
2. Rogers JG, Boyle AJ, O’Connell JB, et al. Risk
assessment and comparative effectiveness of left
ventricular assist device and medical management
in ambulatory heart failure patients: design and
rationale of the ROADMAP clinical trial. Am Heart
J 2015;169:205–10.e20.
3. Slaughter MS, Rogers JG, Milano CA, et al.
Advanced heart failure treated with continuous-
ﬂow left ventricular assist device. N Engl J Med
2009;361:2241–51.
4. Park SJ, Milano CA, Tatooles AJ, et al.
Outcomes in advanced heart failure patients with
left ventricular assist devices for destination
therapy. Circ Heart Fail 2012;5:241–8.
5. Grady KL, Naftel D, Stevenson L, et al. Overall
quality of life improves to similar levels after
mechanical circulatory support regardless of
severity of heart failure before implantation.
J Heart Lung Transplant 2014;33:412–21.
6. Miller LW, Pagani FD, Russell SD, et al.,
Heart Mate II Clinical Investigators. Use of a
continuous-ﬂow device in patients awaiting
heart transplantation. N Engl J Med 2007;357:
885–96.
7. Baldwin JT, Mann DL. NHLBI’s program for VAD
therapy for moderately advanced heart failure: the
REVIVE-IT pilot trial. J Card Fail 2010;16:855–8.
8. HasinT,Marmor Y, KremersW, et al. Readmissions
after implantation of axial ﬂow left ventricular assist
device. J Am Coll Cardiol 2013;61:153–63.
9. Smedira NG, Hoercher KJ, Lima B, et al. Un-
planned hospital readmissions after Heart Mate II
implantation: frequency, risk factors, and impact
on resource use and survival. J Am Coll Cardiol HF
2013;1:31–9.
10. Smedira NG, Blackstone EH, Ehrlinger J, et al.
Current risks of Heart Mate II pump thrombosis:
non-parametric analysis of Interagency
Registry for Mechanically Assisted Circulatory
Support data. J Heart Lung Transplant 2015;34:
1527–34.
11. Teuteberg JJ, Slaughter MS, Rogers JG, et al.,
ADVANCE Trial Investigators. The HVAD Left
Ventricular Assist Device: risk factors for neuro-
logical events and risk mitigation strategies. J Am
Coll Cardiol HF 2015;3:818–28.
12. Stulak JM, Dunlay SM, Sharma S, et al. Treat-
ment of device thrombus in the HeartWare HVAD:
success and outcomes depend signiﬁcantly on the
initial treatment strategy. J Heart Lung Transplant
2015;34:1535–41.
13. Rogers JG. Managing VAD complications: our
growth industry. J Am Coll Cardiol 2016;67:
2769–71.
14. Bruce CR, Blumenthal-Barby JS, Meyers D.
Beneﬁts and challenges of early introduction of
left ventricular assist device placement: a patient-
centered perspective. J Am Coll Cardiol 2015;66:
1762–5.
15. Thompson JS, Matlock DD, McIlvennan CK,
Jenkins AR, Allen LA. Development of a decision
aid for patients with advanced heart failure
considering a destination therapy left ventricular
assist device. J Am Coll Cardiol HF 2015;3:965–76.
16. Mehra M, Naka Y, Uriel N, et al. A fully magnet-
ically levitated circulatory pump for advanced
heart failure. N Engl J Med 2017;376:440–50.
17. Netuka I, Sood P, Pya Y, et al. Fully Magneti-
cally Levitated Left Ventricular Assist System for
Treating Advanced HF: a multicenter study. J Am
Coll Cardiol 2015;66:2579–89.
18. Uriel N, Adatya S, Mehra MR. Evolution in
mechanical circulatory support: are we at the
precipice of a disruptive innovation? J Am Coll
Cardiol 2015;66:2590–3.
KEY WORDS heart failure, left ventricular
assist device, pharmacological therapy
APPENDIX For supplemental tables and
ﬁgures, and acknowledgment of the study
investigators and participating institutions,
please see the online version of this article.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
ROADMAP trial provides the ﬁrst evidence that non–
inotrope-dependent patients electing LVAD therapy will
gain functional capacity and QoL compared with similar
patients electing medical therapy. Although 22% of
patients treated medically received delayed LVADs after
clinical deterioration, their survival rates were equivalent.
AEs are prevalent with both strategies, and readmissions
are not reduced after LVAD. Despite the limitations, LVAD
therapy will be preferred by some patients with advanced
HF who are not yet inotrope dependent. The ROADMAP
trial provides information to assist caregivers when coun-
selling HF patients making important treatment decisions.
TRANSLATIONAL OUTLOOK: LVAD therapy improves
functional capacity and QoL, but not survival, compared with
medical therapy in less ill patients who are non-inotrope
dependent. The observation that QoL and functional capacity
improve despite frequent AEs and frequent need for hospi-
talization is counterintuitive. Patients, in shareddecisionswith
their physicians, should decide what treatment option is
preferred. New technology is needed to reduce LVAD AEs. A
randomized clinical trial in “less ill” patients with new LVAD
technology should be forthcoming with endpoints related to
functional capacity and QoL.
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